Press Releases

Tokyo, Japan, October 17, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has entered into a neurological drug discovery research...

SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, September [26], 2011 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that new data analyses from the lorcaserin Phase 3 clinical...

Woodcliff Lake, NJ , September 2, 2011 -- Eisai Inc. announced today that the company has decided to discontinue global development of rabeprazole sodium extended-release capsules, 50 mg. On...

Woodcliff Lake, NJ, August 30, 2011 - Results presented today of a Phase III pivotal study for the investigational compound perampanel for partial-onset seizures showed that perampanel, 8 mg and...

SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, August 9, 2011 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today results from a Pathology Working Group's (PWG) re-adjudication...

SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 2, 2011 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the completion of a clinical study that measured lorcaserin...

Woodcliff Lake, NJ, July 29, 2011 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug...

Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces that it has entered into a licensing agreement with the Johns Hopkins University's...

Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl...

Eisai Inc. and the Alzheimer's Association announce today that Heather Greene, PharmD is the recipient of the 2009 C.A.R.E. Pharmacy Award. (Photo: http://www.newscom.com/cgi-bin/prnh/20091029/NY00986